Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.43 |
| ▸ | CA1 | P00915 | 11/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31628435 | 0.94 | SYK (0.41) | CA2CA1CA9CA12SERPINE1 | |
| SCHEMBL5413300 | 0.92 | SERPINE1 (0.40) | CA2CA1CA9CA12SERPINE1 | |
| SCHEMBL17250723 | 0.89 | CA2 (0.40) | CA2CA1CA9CA12SERPINE1 | |
| SCHEMBL18551136 | 0.88 | CA2 (0.43) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL22952575 | 0.88 | CA2 (0.43) | CA2CA1CA9CA12SERPINE1 | |
| SCHEMBL21046004 | 0.88 | CA2 (0.43) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL16935947 | 0.88 | CA2 (0.43) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL17664852 | 0.87 | CA2 (0.47) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL24391429 | 0.87 | CA2 (0.42) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL17792643 | 0.87 | PLA2G2C (0.43) | CA2CA1CA9CA12SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-7253296-B2 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2007-08-07 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2006-03-30 | — | — | US | disclosed |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | GENTIF (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-1594486-A2 | USES OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME | Genfit (FR) | 2005-11-16 | — | — | EP | disclosed |
| EP-1592660-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | Genfit (FR) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004073593-A2 | USE OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME FOR DIFFERENT THERAPEUTIC APPLICATIONS | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074239-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| EP-0144825-B1 | CYCLIC GUANIDINYL THIO CARBAPENEMS | MERCK & CO. INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| US-4717728-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1988-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | AASDHPPT, ABAT, AADAC | CA2 1988/4885CA1 611/4885CA9 3281/4885 |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CA2 583/4885CA1 1867/4885CA9 1801/4885 |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | ASS1, SMURF1, SMURF2 | CA2 4057/4885CA1 4831/4885CA9 4161/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | CA2 2518/4885CA1 2462/4885CA9 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.